Pasithea Therapeutics Announces Enrollment of Cohort 2 following Positive Safety Review Committee (SRC) Recommendation for its Ongoing Phase 1/1b Clinical Trial of PAS-004 in Adult NF1 Patients
Provided By GlobeNewswire
Last update: Sep 8, 2025
-- Recommendation that trial escalate to next dose level of 8mg tablet --
-- Initial interim clinical data from first two cohorts expected in Q1 2026 --
NASDAQ:KTTAW (10/9/2025, 9:23:37 PM)
0.0196
+0 (+16.67%)
0.7494
-0.04 (-5.14%)
Find more stocks in the Stock Screener
